Disruption of the γc cytokine network in T cells during HIV infection

Cytokine

Volumn 43, Issue 1, 2008, Pages 1-14

  Sirskyj, Danylo ^a,b   Thèze, Jacques ^c   Kumar, Ashok ^a,b   Kryworuchko, Marko ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c INSTITUT PASTEUR   (France)

Author keywords

Cytokines sharing the Interleukin Receptor common gamma subunit; HAART; HIV; HIV immunotherapy; Signal transduction; T lymphocytes

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 9;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT;

EID: 45449109376     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.03.001     Document Type: Review

References (219)

1. + T-cell depletion in HIV disease. Nature 410 (2001) 974-979
2. McMichael A.J., and Rowland-Jones S.L. Cellular immune responses to HIV. Nature 410 (2001) 980-987
3. Leonard W.J. Cytokines and immunodeficiency diseases. Nat Rev Immunol 1 (2001) 200-208
4. Schluns K.S., and Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 3 (2003) 269-279
5. Kryworuchko M., and Theze J. Interleukin-2: from T cell growth and homeostasis to immune reconstitution of HIV patients. Vitam Horm 74 (2006) 531-547
6. Kryworuchko M., Pasquier V., Keller H., David D., Goujard C., Gilquin J., et al. Defective interleukin-2-dependent STAT5 signalling in CD8 T lymphocytes from HIV-positive patients: restoration by antiretroviral therapy. AIDS 18 (2004) 421-426
7. David D., Bani L., Moreau J.L., Treilhou M.P., Nakarai T., Joussemet M., et al. Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc Natl Acad Sci USA 95 (1998) 11348-11353
8. Fauci A.S. Host factors and the pathogenesis of HIV-induced disease. Nature 384 (1996) 529-534
9. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther 13 (2006) 248-260
10. Olosz F., and Malek T.R. Structural basis for binding multiple ligands by the common cytokine receptor gamma-chain. J Biol Chem 277 (2002) 12047-12052
11. Page T.H., Lali F.V., and Foxwell B.M. Interleukin-7 activates p56lck and p59fyn, two tyrosine kinases associated with the p90 interleukin-7 receptor in primary human T cells. Eur J Immunol 25 (1995) 2956-2960
12. Ellery J.M., and Nicholls P.J. Alternate signalling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev 13 (2002) 27-40
13. Gesbert F., Delespine-Carmagnat M., and Bertoglio J. Recent advances in the understanding of interleukin-2 signal transduction. J Clin Immunol 18 (1998) 307-320
14. Murray P.J. The JAK-STAT signaling pathway: input and output integration. J Immunol 178 (2007) 2623-2629
15. Decker T., and Kovarik P. Serine phosphorylation of STATs. Oncogene 19 (2000) 2628-2637
16. Dong C., Davis R.J., and Flavell R.A. MAP kinases in the immune response. Annu Rev Immunol 20 (2002) 55-72
17. Koyasu S. The role of PI3K in immune cells. Nat Immunol 4 (2003) 313-319
18. Morgan D.A., Ruscetti F.W., and Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193 (1976) 1007-1008
19. Gaffen S.L., and Liu K.D. Overview of interleukin-2 function, production and clinical applications. Cytokine 28 (2004) 109-123
20. Romagnani S. Regulation of the T cell response. Clin Exp Allergy 36 (2006) 1357-1366
21. Granucci F., Vizzardelli C., Pavelka N., Feau S., Persico M., Virzi E., et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol 2 (2001) 882-888
22. Lenardo M., Chan K.M., Hornung F., McFarland H., Siegel R., Wang J., et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17 (1999) 221-253
23. Refaeli Y., Van Parijs L., London C.A., Tschopp J., and Abbas A.K. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8 (1998) 615-623
24. Van Parijs L., and Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280 (1998) 243-248
25. Malek T.R., and Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4 (2004) 665-674
26. Theze J., Alzari P.M., and Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol Today 17 (1996) 481-486
27. Nelson B.H. IL-2, regulatory T cells, and tolerance. J Immunol 172 (2004) 3983-3988
28. Bach J.F. Regulatory T cells under scrutiny. Nat Rev Immunol 3 (2003) 189-198
29. + T cell numbers. J Immunol 169 (2002) 4850-4860
30. Lenardo M.J. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 353 (1991) 858-861
31. Malek T.R., Yu A., Vincek V., Scibelli P., and Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17 (2002) 167-178
32. + regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 6 (2005) 1152-1159
33. Fontenot J.D., Rasmussen J.P., Gavin M.A., and Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6 (2005) 1142-1151
34. Lin J.X., and Leonard W.J. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 19 (2000) 2566-2576
35. + T lymphocytes. J Immunol 179 (2007) 3596-3603
36. Lin J.X., Migone T.S., Tsang M., Friedmann M., Weatherbee J.A., Zhou L., et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2 (1995) 331-339
37. White L., Krishnan S., Strbo N., Liu H., Kolber M.A., Lichtenheld M.G., et al. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV). Blood 109 (2007) 3873-3880
38. + patients is associated with the transcriptional repressor Gfi-1 and impaired STAT activation in response to IL-7 but not IL-2, IL-15, IL-4, and IL-10. (manuscript in preparation).
39. + patients: role in pathogenesis. Ontario HIV treatment network research conference, November 2005, Toronto, Ontario, Canada.
40. Gonzalez-Garcia A., Merida I., Martinez A., and Carrera A.C. Intermediate affinity interleukin-2 receptor mediates survival via a phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem 272 (1997) 10220-10226
41. Moriggl R., Topham D.J., Teglund S., Sexl V., McKay C., Wang D., et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10 (1999) 249-259
42. Martino A., Holmes J.H., Lord J.D., Moon J.J., and Nelson B.H. Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J Immunol 166 (2001) 1723-1729
43. Matsumoto A., Masuhara M., Mitsui K., Yokouchi M., Ohtsubo M., Misawa H., et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89 (1997) 3148-3154
44. Gesbert F., Delespine-Carmagnat M., and Bertoglio J. Tyrosine kinase substrates in interleukin-2 signaling. Eur Cytokine Netw 9 (1998) 33-40
45. Miyazaki T., Liu Z.J., Kawahara A., Minami Y., Yamada K., Tsujimoto Y., et al. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 81 (1995) 223-231
46. Hauser G.J., Bino T., Rosenberg H., Zakuth V., Geller E., and Spirer Z. Interleukin-2 production and response to exogenous interleukin-2 in a patient with the acquired immune deficiency syndrome (AIDS). Clin Exp Immunol 56 (1984) 14-17
47. Clerici M., Hakim F.T., Venzon D.J., Blatt S., Hendrix C.W., Wynn T.A., et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 91 (1993) 759-765
48. Clerici M., and Shearer G.M. A TH1 TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 14 (1993) 107-111
49. Notermans D.W., Jurriaans S., de Wolf F., Foudraine N.A., de Jong J.J., Cavert W., et al. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group. AIDS 12 (1998) 167-173
50. Mosmann T.R., and Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7 (1989) 145-173
51. Nelms K., Keegan A.D., Zamorano J., Ryan J.J., and Paul W.E. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17 (1999) 701-738
52. Yoshimoto T., and Paul W.E. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 179 (1994) 1285-1295
53. Gibbs B.F. Human basophils as effectors and immunomodulators of allergic inflammation and innate immunity. Clin Exp Med 5 (2005) 43-49
54. Prussin C., and Metcalfe D.D. 4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 111 (2003) S486-S494
55. Haas H., Falcone F.H., Holland M.J., Schramm G., Haisch K., Gibbs B.F., et al. Early interleukin-4: its role in the switch towards a Th2 response and IgE-mediated allergy. Int Arch Allergy Immunol 119 (1999) 86-94
56. Acres R.B., Widmer M.B., Grabstein K.H., and Gillis S. Regulation of human T-cell proliferation and CTL development by human recombinant interleukin-4. Ann N Y Acad Sci 532 (1988) 1-7
57. + T cells. J Leukoc Biol 81 (2007) 1102-1110
58. Kovanen P.E., and Leonard W.J. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev 202 (2004) 67-83
59. Clerici M., and Shearer G.M. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 15 (1994) 575-581
60. Lucey D.R., Clerici M., and Shearer G.M. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9 (1996) 532-562
61. Fakoya A., Matear P.M., Filley E., Rook G.A., Stanford J., Gilson R.J., et al. HIV infection alters the production of both type 1 and 2 cytokines but does not induce a polarized type 1 or 2 state. AIDS 11 (1997) 1445-1452
62. Graziosi C., Pantaleo G., Gantt K.R., Fortin J.P., Demarest J.F., Cohen O.J., et al. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 265 (1994) 248-252
63. - T cells. Scand J Immunol 50 (1999) 550-554
64. Diaz-Mitoma F., Kumar A., Karimi S., Kryworuchko M., Daftarian M.P., Creery W.D., et al. Expression of IL-10, IL-4 and interferon-gamma in unstimulated and mitogen-stimulated peripheral blood lymphocytes from HIV-seropositive patients. Clin Exp Immunol 102 (1995) 31-39
65. Levy J.A. HIV pathogenesis and long-term survival. AIDS 7 (1993) 1401-1410
66. Vigano A., Principi N., Villa M.L., Riva C., Crupi L., Trabattoni D., et al. Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression. J Pediatr 126 (1995) 368-374
67. Vigano A., Principi N., Crupi L., Onorato J., Vincenzo Z.G., and Salvaggio A. Elevation of IgE in HIV-infected children and its correlation with the progression of disease. J Allergy Clin Immunol 95 (1995) 627-632
68. + T-cells. AIDS Res Hum Retroviruses 6 (1990) 427-429
69. Israel-Biet D., Labrousse F., Tourani J.M., Sors H., Andrieu J.M., and Even P. Elevation of IgE in HIV-infected subjects: a marker of poor prognosis. J Allergy Clin Immunol 89 (1992) 68-75
70. Miguez-Burbano M.J., Shor-Posner G., Fletcher M.A., Lu Y., Moreno J.N., Carcamo C., et al. Immunoglobulin E levels in relationship to HIV-1 disease, route of infection, and vitamin E status. Allergy 50 (1995) 157-161
71. Wright D.N., Nelson Jr. R.P., Ledford D.K., Fernandez-Caldas E., Trudeau W.L., and Lockey R.F. Serum IgE and human immunodeficiency virus (HIV) infection. J Allergy Clin Immunol 85 (1990) 445-452
72. Mirza O., Henriksen A., Ipsen H., Larsen J.N., Wissenbach M., Spangfort M.D., et al. Dominant epitopes and allergic cross-reactivity: complex formation between a Fab fragment of a monoclonal murine IgG antibody and the major allergen from birch pollen Bet v 1. J Immunol 165 (2000) 331-338
73. Becker Y. The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers-a review and hypothesis. Virus Genes 28 (2004) 5-18
74. Horikoshi H., Kinomoto M., Kurosu T., Komoto S., Shiraga M., Otake T., et al. Resting CD4(+) T cells with CD38(+)CD62L(+) produce interleukin-4 which contributes to enhanced replication of T-tropic human immunodeficiency virus type 1. Virology 293 (2002) 94-102
75. Soriano A., Lozano F., Oliva H., Garcia F., Nomdedeu M., De Lazzari E., et al. Polymorphisms in the interleukin-4 receptor α chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. Immunogenetics 57 (2005) 644-654
76. Do H., Vasilescu A., Diop G., Hirtzig T., Coulonges C., Labib T., et al. Associations of the IL2Rα, IL4Rα, IL10Rα, and IFN (γ) R1 cytokine receptor genes with AIDS progression in a French AIDS cohort. Immunogenetics 58 (2006) 89-98
77. Wang C., Song W., Lobashevsky E., Wilson C.M., Douglas S.D., Mytilineos J., et al. Cytokine and chemokine gene polymorphisms among ethnically diverse North Americans with HIV-1 infection. J Acquir Immune Defic Syndr 35 (2004) 446-454
78. + patients is associated with the transcriptional repressor Gfi-1 and impaired STAT activation in response to IL-7 but not IL-2, IL-15, IL-4, and IL-10. In: Fourth international conference on HIV pathogenesis, treatment and prevention, July 2007, Sydney, Australia.
79. Bradley L.M., Haynes L., and Swain S.L. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol 26 (2005) 172-176
80. Mazzucchelli R., and Durum S.K. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 7 (2007) 144-154
81. Sasson S.C., Zaunders J.J., and Kelleher A.D. The IL-7/IL-7 receptor axis: understanding its central role in T-cell homeostasis and the challenges facing its utilization as a novel therapy. Curr Drug Targets 7 (2006) 1571-1582
82. Ariizumi K., Meng Y., Bergstresser P.R., and Takashima A. IFN-γ-dependent IL-7 gene regulation in keratinocytes. J Immunol 154 (1995) 6031-6039
83. Tang J., Nuccie B.L., Ritterman I., Liesveld J.L., Abboud C.N., and Ryan D.H. TGF-β down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors. J Immunol 159 (1997) 117-125
84. Foxwell B.M., Beadling C., Guschin D., Kerr I., and Cantrell D. Interleukin-7 can induce the activation of Jak 1, Jak 3 and STAT 5 proteins in murine T cells. Eur J Immunol 25 (1995) 3041-3046
85. Hofmeister R., Khaled A.R., Benbernou N., Rajnavolgyi E., Muegge K., and Durum S.K. Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev 10 (1999) 41-60
86. Rosenthal L.A., Winestock K.D., and Finbloom D.S. IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts. Cell Immunol 181 (1997) 172-181
87. Sharfe N., Dadi H.K., and Roifman C.M. JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of phosphatidylinositol-3′ kinase. Blood 86 (1995) 2077-2085
88. Dadi H., Ke S., and Roifman C.M. Activation of phosphatidylinositol-3 kinase by ligation of the interleukin-7 receptor is dependent on protein tyrosine kinase activity. Blood 84 (1994) 1579-1586
89. Sharfe N., and Roifman C.M. Differential association of phosphatidylinositol 3-kinase with insulin receptor substrate (IRS)-1 and IRS-2 in human thymocytes in response to IL-7. J Immunol 159 (1997) 1107-1114
90. Franke T.F., Kaplan D.R., and Cantley L.C. PI3K: downstream AKTion blocks apoptosis. Cell 88 (1997) 435-437
91. Crawley J.B., Willcocks J., and Foxwell B.M. Interleukin-7 induces T cell proliferation in the absence of Erk/MAP kinase activity. Eur J Immunol 26 (1996) 2717-2723
92. Crawley J.B., Rawlinson L., Lali F.V., Page T.H., Saklatvala J., and Foxwell B.M. T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J Biol Chem 272 (1997) 15023-15027
93. Khaled A.R., and Durum S.K. Death and Baxes: mechanisms of lymphotrophic cytokines. Immunol Rev 193 (2003) 48-57
94. + effector and memory T cell generation. Nat Immunol 4 (2003) 835-842
95. Geginat J., Sallusto F., and Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med 194 (2001) 1711-1719
96. Sallusto F., Lenig D., Forster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 (1999) 708-712
97. + T-cell immune responses. Blood 107 (2006) 2855-2862
98. Xue H.H., Kovanen P.E., Pise-Masison C.A., Berg M., Radovich M.F., Brady J.N., et al. IL-2 negatively regulates IL-7 receptor α chain expression in activated T lymphocytes. Proc Natl Acad Sci USA 99 (2002) 13759-13764
99. Rethi B., Fluur C., Atlas A., Krzyzowska M., Mowafi F., Grutzmeier S., et al. Loss of IL-7Rα is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. AIDS 19 (2005) 2077-2086
100. Sasson S.C., Zaunders J.J., Zanetti G., King E.M., Merlin K.M., Smith D.E., et al. Increased plasma interleukin-7 level correlates with decreased CD127 and increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection. J Infect Dis 193 (2006) 505-514
101. + T cells in HIV-infected individuals. J Immunol 174 (2005) 2900-2909
102. Park J.H., Yu Q., Erman B., Appelbaum J.S., Montoya-Durango D., Grimes H.L., et al. Suppression of IL7Rα transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 21 (2004) 289-302
103. Xue H.H., Bollenbacher J., Rovella V., Tripuraneni R., Du Y.B., Liu C.Y., et al. GA binding protein regulates interleukin 7 receptor α-chain gene expression in T cells. Nat Immunol 5 (2004) 1036-1044
104. Dekoter R.P., Schweitzer B.L., Kamath M.B., Jones D., Tagoh H., Bonifer C., et al. Regulation of the interleukin-7 receptor α promoter by the Ets transcription factors PU. 1 and GA-binding protein in developing B cells. J Biol Chem 282 (2007) 14194-14204
105. Kim H.R., Hwang K.A., Kim K.C., and Kang I. Down-regulation of IL-7R{α} expression in human T cells via DNA methylation. J Immunol 178 (2007) 5473-5479
106. Carini C., McLane M.F., Mayer K.H., and Essex M. Dysregulation of interleukin-7 receptor may generate loss of cytotoxic T cell response in human immunodeficiency virus type 1 infection. Eur J Immunol 24 (1994) 2927-2934
107. Albuquerque A.S., Cortesao C.S., Foxall R.B., Soares R.S., Victorino R.M., and Sousa A.E. Rate of increase in circulating IL-7 and loss of IL-7Rα expression differ in HIV-1 and HIV-2 infections: two lymphopenic diseases with similar hyperimmune activation but distinct outcomes. J Immunol 178 (2007) 3252-3259
108. Napolitano L.A., Grant R.M., Deeks S.G., Schmidt D., De Rosa S.C., Herzenberg L.A., et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 7 (2001) 73-79
109. Fry T.J., Connick E., Falloon J., Lederman M.M., Liewehr D.J., Spritzler J., et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 97 (2001) 2983-2990
110. Llano A., Barretina J., Gutierrez A., Blanco J., Cabrera C., Clotet B., et al. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J Virol 75 (2001) 10319-10325
111. Mastroianni C.M., Forcina G., D'Ettorre G., Lichtner M., Mengoni F., D'Agostino C., et al. Circulating levels of interleukin-7 in antiretroviral-naive and highly active antiretroviral therapy-treated HIV-infected patients. HIV Clin Trials 2 (2001) 108-112
112. Boulassel M.R., Young M., Routy J.P., Sekaly R.P., Tremblay C., and Rouleau D. Circulating levels of IL-7 but not IL-15, IGF-1, and TGF-β are elevated during primary HIV-1 infection. HIV Clin Trials 5 (2004) 357-359
113. Fluur C., Rethi B., Thang P.H., Vivar N., Mowafi F., Lopalco L., et al. Relationship between serum IL-7 concentrations and lymphopenia upon different levels of HIV immune control. AIDS 21 (2007) 1048-1050
114. Fluur C., De Milito A., Fry T.J., Vivar N., Eidsmo L., Atlas A., et al. Potential role for IL-7 in Fas-mediated T cell apoptosis during HIV infection. J Immunol 178 (2007) 5340-5350
115. + T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis. J Immunol 171 (2003) 61-68
116. Managlia E.Z., Landay A., and Al Harthi L. Interleukin-7 signalling is sufficient to phenotypically and functionally prime human CD4 naive T cells. Immunology 114 (2005) 322-335
117. Lelievre J.D., Petit F., Arnoult D., Ameisen J.C., and Estaquier J. Interleukin 7 increases human immunodeficiency virus type 1 LAI-mediated Fas-induced T-cell death. J Virol 79 (2005) 3195-3199
118. Boutboul F., Puthier D., Appay V., Pelle O., Ait-Mohand H., Combadiere B., et al. Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV. AIDS 19 (2005) 1981-1986
119. Colle J.H., Moreau J.L., Fontanet A., Lambotte O., Joussemet M., Jacod S., et al. Regulatory dysfunction of the interleukin-7 receptor in CD4 and CD8 lymphocytes from HIV-infected patients-effects of antiretroviral therapy. J Acquir Immune Defic Syndr 42 (2006) 277-285
120. + T lymphocytes decreases with HIV disease progression and inversely correlates with immune activation. Eur J Immunol 36 (2006) 336-344
121. MacPherson P.A., Fex C., Sanchez-Dardon J., Hawley-Foss N., and Angel J.B. Interleukin-7 receptor expression on CD8(+) T cells is reduced in HIV infection and partially restored with effective antiretroviral therapy. J Acquir Immune Defic Syndr 28 (2001) 454-457
122. Vingerhoets J., Bisalinkumi E., Penne G., Colebunders R., Bosmans E., Kestens L., et al. Altered receptor expression and decreased sensitivity of T-cells to the stimulatory cytokines IL-2, IL-7 and IL-12 in HIV infection. Immunol Lett 61 (1998) 53-61
123. Faller E.M., McVey M.J., Kakal J.A., and MacPherson P.A. Interleukin-7 receptor expression on CD8 T-cells is downregulated by the HIV Tat protein. J Acquir Immune Defic Syndr 43 (2006) 257-269
124. Colle J.H., Moreau J.L., Fontanet A., Lambotte O., Delfraissy J.F., and Theze J. The correlation between levels of IL-7Rα expression and responsiveness to IL-7 is lost in CD4 lymphocytes from HIV-infected patients. AIDS 21 (2007) 101-103
125. + T cells from HIV-1-infected individuals. Proc Natl Acad Sci USA 104 (2007) 2355-2360
126. Burton J.D., Bamford R.N., Peters C., Grant A.J., Kurys G., Goldman C.K., et al. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 91 (1994) 4935-4939
127. Grabstein K.H., Eisenman J., Shanebeck K., Rauch C., Srinivasan S., Fung V., et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264 (1994) 965-968
128. Alpdogan O., and van den Brink M.R. IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol 26 (2005) 56-64
129. Budagian V., Bulanova E., Paus R., and Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 17 (2006) 259-280
130. Bulfone-Paus S., Bulanova E., Budagian V., and Paus R. The interleukin-15/interleukin-15 receptor system as a model for juxtacrine and reverse signaling. Bioessays 28 (2006) 362-377
131. Orinska Z., Maurer M., Mirghomizadeh F., Bulanova E., Metz M., Nashkevich N., et al. IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. Nat Med 13 (2007) 927-934
132. Carson W.E., Fehniger T.A., Haldar S., Eckhert K., Lindemann M.J., Lai C.F., et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99 (1997) 937-943
133. Evans R., Fuller J.A., Christianson G., Krupke D.M., and Troutt A.B. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell Immunol 179 (1997) 66-73
134. Marks-Konczalik J., Dubois S., Losi J.M., Sabzevari H., Yamada N., Feigenbaum L., et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 97 (2000) 11445-11450
135. Prlic M., Blazar B.R., Farrar M.A., and Jameson S.C. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 197 (2003) 967-976
136. + T cells in vitro. Blood 102 (2003) 2541-2546
137. + T cells. J Immunol 170 (2003) 5018-5026
138. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191 (2000) 771-780
139. Matsuda J.L., Gapin L., Sidobre S., Kieper W.C., Tan J.T., Ceredig R., et al. Homeostasis of V alpha 14i NKT cells. Nat Immunol 3 (2002) 966-974
140. + T cells in vivo by IL-15. Immunity 8 (1998) 591-599
141. Dubois S., Mariner J., Waldmann T.A., and Tagaya Y. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 17 (2002) 537-547
142. Schluns K.S., Klonowski K.D., and Lefrancois L. Transregulation of memory CD8 T-cell proliferation by IL-15Rα+ bone marrow-derived cells. Blood 103 (2004) 988-994
143. Johnston J.A., Bacon C.M., Finbloom D.S., Rees R.C., Kaplan D., Shibuya K., et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA 92 (1995) 8705-8709
144. Zambricki E., Shigeoka A., Kishimoto H., Sprent J., Burakoff S., Carpenter C., et al. Signaling T-cell survival and death by IL-2 and IL-15. Am J Transplant 5 (2005) 2623-2631
145. Kacani L., Stoiber H., and Dierich M.P. Role of IL-15 in HIV-1-associated hypergammaglobulinaemia. Clin Exp Immunol 108 (1997) 14-18
146. Ahmad R., Sindhu S.T., Toma E., Morisset R., and Ahmad A. Studies on the production of IL-15 in HIV-infected/AIDS patients. J Clin Immunol 23 (2003) 81-90
147. Ahmad A., Ahmad R., Toma E., Morisset R., and Menezes J. Impaired induction of IL-15 in response to herpes simplex virus type 1 infection in peripheral blood mononuclear cells of HIV-infected patients. AIDS 14 (2000) 744-746
148. Chehimi J., Marshall J.D., Salvucci O., Frank I., Chehimi S., Kawecki S., et al. IL-15 enhances immune functions during HIV infection. J Immunol 158 (1997) 5978-5987
149. D'Ettorre G., Forcina G., Lichtner M., Mengoni F., D'Agostino C., Massetti A.P., et al. Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients. AIDS 16 (2002) 181-188
150. Appay V., Nixon D.F., Donahoe S.M., Gillespie G.M., Dong T., King A., et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192 (2000) 63-75
151. Champagne P., Ogg G.S., King A.S., Knabenhans C., Ellefsen K., Nobile M., et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410 (2001) 106-111
152. + T cells. Blood 101 (2003) 2711-2720
153. + T cells. Blood 101 (2003) 1024-1029
154. + effector-memory T cells. Int Immunol 15 (2003) 49-58
155. Agostini C., Trentin L., Sancetta R., Facco M., Tassinari C., Cerutti A., et al. Interleukin-15 triggers activation and growth of the CD8 T-cell pool in extravascular tissues of patients with acquired immunodeficiency syndrome. Blood 90 (1997) 1115-1123
156. + T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2. J Infect Dis 187 (2003) 1735-1747
157. Chae D.W., Nosaka Y., Strom T.B., and Maslinski W. Distribution of IL-15 receptor alpha-chains on human peripheral blood mononuclear cells and effect of immunosuppressive drugs on receptor expression. J Immunol 157 (1996) 2813-2819
158. + T cells in HIV disease exhibit cytokine receptor perturbation and poor T cell receptor activation but are responsive to gamma-chain cytokine-driven proliferation. J Infect Dis 193 (2006) 879-887
159. Knoops L., and Renauld J.C. IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors 22 (2004) 207-215
160. Houssiau F.A., Schandene L., Stevens M., Cambiaso C., Goldman M., Van Snick J., et al. A cascade of cytokines is responsible for IL-9 expression in human T cells. Involvement of IL-2, IL-4, and IL-10. J Immunol 154 (1995) 2624-2630
161. Bauer J.H., Liu K.D., You Y., Lai S.Y., and Goldsmith M.A. Heteromerization of the gamma chain with the interleukin-9 receptor alpha subunit leads to STAT activation and prevention of apoptosis. J Biol Chem 273 (1998) 9255-9260
162. Demoulin J.B., Van Roost E., Stevens M., Groner B., and Renauld J.C. Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9. J Biol Chem 274 (1999) 25855-25861
163. Xiao H., Yin T., Wang X.Y., Uchida T., Chung J., White M.F., et al. Specificity of interleukin-2 receptor gamma chain superfamily cytokines is mediated by insulin receptor substrate-dependent pathway. J Biol Chem 277 (2002) 8091-8098
164. Demoulin J.B., Louahed J., Dumoutier L., Stevens M., and Renauld J.C. MAP kinase activation by interleukin-9 in lymphoid and mast cell lines. Oncogene 22 (2003) 1763-1770
165. + T cells producing anti-human immunodeficiency virus type 1 substance(s). Acta Virol 42 (1998) 47-53
166. Asao H., Okuyama C., Kumaki S., Ishii N., Tsuchiya S., Foster D., et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 167 (2001) 1-5
167. Ozaki K., Kikly K., Michalovich D., Young P.R., and Leonard W.J. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA 97 (2000) 11439-11444
168. Leonard W.J., and Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 5 (2005) 688-698
169. Strengell M., Julkunen I., and Matikainen S. IFN-α regulates IL-21 and IL-21R expression in human NK and T cells. J Leukoc Biol 76 (2004) 416-422
170. + T cell expansion and function. J Exp Med 201 (2005) 139-148
171. Zeng R., Spolski R., Casas E., Zhu W., Levy D.E., and Leonard W.J. The molecular basis of IL-21-mediated proliferation. Blood 109 (2007) 4135-4142
172. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57-63
173. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B., et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16 (2002) 559-569
174. Parrish-Novak J., Foster D.C., Holly R.D., and Clegg C.H. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 72 (2002) 856-863
175. Wurster A.L., Rodgers V.L., Satoskar A.R., Whitters M.J., Young D.A., Collins M., et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med 196 (2002) 969-977
176. King C., Ilic A., Koelsch K., and Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117 (2004) 265-277
177. + T cells upon antigenic stimulation. Int Immunol 17 (2005) 713-719
178. Stevenson M., Stanwick T.L., Dempsey M.P., and Lamonica C.A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 9 (1990) 1551-1560
179. Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., and Chen I.S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61 (1990) 213-222
180. + T cells. Nature 435 (2005) 108-114
181. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (2002) 646-650
182. Unutmaz D., KewalRamani V.N., Marmon S., and Littman D.R. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med 189 (1999) 1735-1746
183. Kreisberg J.F., Yonemoto W., and Greene W.C. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med 203 (2006) 865-870
184. Stopak K.S., Chiu Y.L., Kropp J., Grant R.M., and Greene W.C. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem 282 (2007) 3539-3546
185. Freeman G.J., Wherry E.J., Ahmed R., and Sharpe A.H. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 203 (2006) 2223-2227
186. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 (2006) 350-354
187. + T cell survival in HIV infection. J Exp Med 203 (2006) 2281-2292
188. + T cells leads to reversible immune dysfunction. Nat Med 12 (2006) 1198-1202
189. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200 (2004) 749-759
190. + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 77 (2003) 11708-11717
191. + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200 (2004) 761-770
192. Nilsson J., Kinloch-de-Loes S., Granath A., Sonnerborg A., Goh L.E., and Andersson J. Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. AIDS 21 (2007) 565-574
193. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998) 853-860
194. Grant R.M., Hecht F.M., Warmerdam M., Liu L., Liegler T., Petropoulos C.J., et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288 (2002) 181-188
195. Parkin N.T., Lie Y.S., Hellmann N., Markowitz M., Bonhoeffer S., Ho D.D., et al. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. J Infect Dis 180 (1999) 865-870
196. Marchetti G., Franzetti F., and Gori A. Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?. J Antimicrob Chemother 55 (2005) 401-409
197. Lane H.C., Siegel J.P., Rook A.H., Masur H., Gelmann E.P., Quinnan G.V., et al. Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J Biol Response Mod 3 (1984) 512-516
198. Pau A.K., and Tavel J.A. Therapeutic use of interleukin-2 in HIV-infected patients. Curr Opin Pharmacol 2 (2002) 433-439
199. Emery S., Capra W.B., Cooper D.A., Mitsuyasu R.T., Kovacs J.A., Vig P., et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis 182 (2000) 428-434
200. David D., Nait-Ighil L., Dupont B., Maral J., Gachot B., and Theze J. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J Infect Dis 183 (2001) 730-735
201. David D., Keller H., Nait-Ighil L., Treilhou M.P., Joussemet M., Dupont B., et al. Involvement of Bcl-2 and IL-2R in HIV-positive patients whose CD4 cell counts fail to increase rapidly with highly active antiretroviral therapy. AIDS 16 (2002) 1093-1101
202. Mitsuyasu R., Gelman R., Cherng D.W., Landay A., Fahey J., Reichman R., et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial-AIDS Clinical Trials Group 328. Arch Intern Med 167 (2007) 597-605
203. Youle M., Emery S., Fisher M., Nelson M., Fosdick L., Janossy G., et al. A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study. PLoS Clin Trials 1 (2006) e3
204. Lentsch A.B., Miller F.N., and Edwards M.J. Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol Immunother 47 (1999) 243-248
205. Locker G.J., Kapiotis S., Veitl M., Mader R.M., Stoiser B., Kofler J., et al. Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. Br J Haematol 105 (1999) 912-919
206. + T cells in vivo after IL-2 treatment of patients with HIV infection. Proc Natl Acad Sci USA 99 (2002) 10712-10717
207. Sereti I., Martinez-Wilson H., Metcalf J.A., Baseler M.W., Hallahan C.W., Hahn B., et al. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. Blood 100 (2002) 2159-2167
208. + T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 104 (2004) 775-780
209. + regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78 (2004) 2454-2459
210. Kinter A.L., Hennessey M., Bell A., Kern S., Lin Y., Daucher M., et al. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 200 (2004) 331-343
211. + regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 104 (2004) 3249-3256
212. + T-regulatory cells. J Immunother 29 (2006) 313-319
213. Chenier R. T cell dynamics in IL-7 treated Rhesus macaques, application to the clinic. In: Symposium, fourth international conference on HIV pathogenesis, treatment and prevention, July 2007, Sydney, Australia.
214. Safety study of IL-7 in HIV-infected patients. National Institute of Allergy and Infectious Diseases (NIAID). Available from: http://www.clinicaltrials.gov/ct/show/NCT00115960?order=1.
215. Munger W., DeJoy S.Q., Jeyaseelan Sr. R., Torley L.W., Grabstein K.H., Eisenmann J., et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 165 (1995) 289-293
216. Tsunobuchi H., Nishimura H., Goshima F., Daikoku T., Suzuki H., Nakashima I., et al. A protective role of interleukin-15 in a mouse model for systemic infection with herpes simplex virus. Virology 275 (2000) 57-66
217. Safety and effectiveness of PENNVAX-B vaccine alone, with IL-12, or IL-15 in healthy adults. National Institute of Allergy and Infectious Diseases (NIAID). Available from: http://www.clinicaltrials.gov/ct/show/NCT00528489?order=3.
218. Safety of and immune response to an HIV preventive vaccine (HIV-1 Gag DNA alone or with IL-15 DNA) given with or without 2 different booster vaccinations in HIV uninfected Adults. National Institute of Allergy and Infectious Diseases (NIAID). Available from: http://www.clinicaltrials.gov/ct/show/NCT00115960?order=1.
219. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983) 868-871